RadioMedix’s 225Ac-PSMA-I&T Program Acquired by Fusion Pharmaceuticals
Gunderson Dettmer represented client RadioMedix Inc., a clinical-stage biotechnology company, in the acquisition of its 225Ac-PSMA-I&T program, a Targeted Alpha Therapy (TAT) for metastatic castration-resistant prostate cancer, by Fusion Pharmaceuticals Inc. RadioMedix develops innovative targeted radiopharmaceuticals for diagnostic imaging and therapy of cancer designed to improve patient outcomes and quality of life. Through this acquisition, the two companies can support further development of commercialization for this promising therapy.
In the announcement of the acquisition, Chairman and CEO of RadioMedix Ebrahim Delpassand, M.D. said, “Having treated mCRPC patients for many years, we initiated the TATCIST trial to evaluate TAT in this group of patients with this catastrophic illness. Given Fusion’s radiopharmaceutical development capabilities, leadership in actinium supply, and established infrastructure, this company is in the best position in developing 225Ac radiopharmaceuticals. This was one of our main incentives to partner with Fusion to advance this drug through clinical development in the most time-effective and practical way, so this drug becomes commercially available to patients, as soon as possible.”
The Gunderson Dettmer deal team was led by Wes Watts and Alex Devine, and included Ben Cukerbaum, Melissa Brekke and Sean Patrick McGinley.
Fusion Pharmaceuticals Inc